Ashland Stock Earnings Reports

Key points for investors: Ashland reported Q1 sales of $386 million (down 5% year-over-year; down 3% ex-Evoqua divestiture) and adjusted EBITDA of $58 million (down 5% YoY; excluding Evoqua adjusted EBITDA rose ~3%). Adjusted EBITDA margin was 15% (pressure from the Calvert City outage). Life Sciences (+4% sales) was the strongest segment—driven by pharma, injectables, tablet coatings and high‑value cellulosic excipients—with EBITDA up 11% and margins expanding to 22.3%. Personal Care was broadly stable (organic down ~1% excluding Evoqua), with strong growth in biofunctional actives and microbial protection; adjusted EBITDA was $26 million and margins ~21.1%. Specialty Additives sales declined (‑11%) due to coatings and construction weakness (China and select export markets), but EBITDA increased 15% and margin expanded to 14.7% thanks to productivity and HCC consolidation. Intermediates remain challenged (sales $31 million; EBITDA $1 million) from trough BDO dynamics and Calvert City upstream impacts.

Operational and cash highlights: operating cash flow $125 million, ongoing free cash flow $26 million (seasonally low quarter), liquidity approximately $900 million, net debt $1.1 billion and net leverage ~2.7x. Ashland reiterated cost-savings/program targets: ~$30 million restructuring target for FY26 (on track) and $50–55 million manufacturing optimization target (with upside to $60M). Innovate and Globalize early-year traction: $6 million of incremental innovation sales and $3 million of Globalize sales YTD toward a combined FY26 target of $35 million.

Headwinds and guidance: Repairs and commissioning delays at Calvert City plus weather-related site outages extended some impacts into Q2; the company quantified approximately $11 million of temporary impacts isolated to Q2 (roughly two-thirds volume/absorption and one-third incremental costs), with much of the volume impact recoverable beginning once units return to normal rates (expected recovery beginning in Q3). Ashland narrowed FY26 adjusted EBITDA guidance to $400–420 million and reiterated a second-half weighted recovery, emphasizing disciplined capital allocation, continued execution of productivity plans, and confidence in the Innovate/Globalize growth levers.